000 01635 a2200433 4500
005 20250515173911.0
264 0 _c20091202
008 200912s 0 0 eng d
022 _a1439-4286
024 7 _a10.1055/s-0029-1224116
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aPapewalis, C
245 0 0 _aRole of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer.
_h[electronic resource]
260 _bHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
_cOct 2009
300 _a752-6 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aCarcinoma
_xdrug therapy
650 0 4 _aCell Line, Tumor
650 0 4 _aCell Proliferation
_xdrug effects
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aEverolimus
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xpharmacology
650 0 4 _aProliferating Cell Nuclear Antigen
_xgenetics
650 0 4 _aProtein Kinases
_xgenetics
650 0 4 _aRNA
_xchemistry
650 0 4 _aReverse Transcriptase Polymerase Chain Reaction
650 0 4 _aSirolimus
_xanalogs & derivatives
650 0 4 _aTOR Serine-Threonine Kinases
650 0 4 _aThyroid Neoplasms
_xdrug therapy
700 1 _aWuttke, M
700 1 _aSchinner, S
700 1 _aWillenberg, H S
700 1 _aBaran, A M
700 1 _aScherbaum, W A
700 1 _aSchott, M
773 0 _tHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
_gvol. 41
_gno. 10
_gp. 752-6
856 4 0 _uhttps://doi.org/10.1055/s-0029-1224116
_zAvailable from publisher's website
999 _c18933960
_d18933960